human chorionic gonadotropin-activated autologous peripheral blood mononuclear cells

Human chorionic gonadotropin-activated autologous peripheral blood mononuclear cells is an autologous cell-based immunotherapy used to treat recurrent implantation failure (RIF) and recurrent miscarriage (RM) in patients undergoing in vitro fertilization (IVF). The therapy involves isolating peripheral blood mononuclear cells (PBMCs)—including T and B lymphocytes, monocytes, and macrophages—from the patient's own blood and activating them in vitro with human chorionic gonadotropin (hCG) for 24 to 48 hours. The activated cells are then administered intrauterinely 2 to 3 days before embryo transfer. The biological mechanism involves the stimulation of pro-implantation cytokines such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and leukemia inhibitory factor (LIF), as well as the upregulation of matrix metalloproteinases (MMP-2 and MMP-9). These factors collectively improve endometrial receptivity and promote trophoblast invasion, thereby increasing implantation and pregnancy rates in patients with a history of multiple IVF failures.

Other names

hCG-activated PBMChCG-activated autologous PBMCIntrauterine administration of hCG-activated peripheral blood mononuclear cells